Join to View Full Profile
140 Jfk DrAtlantis, FL 33462
Phone+1 561-968-6767
Dr. Goldstein is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Stanford Health Care-Sponsored Stanford UniversityResidency, Neurology, 1980 - 1983
Rutgers Health/New Jersey Medical SchoolResidency, Internal Medicine, 1977 - 1980
Emory University School of MedicineClass of 1977
Certifications & Licensure
FL State Medical License 1983 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Psychiatry and Neurology Neurology
Clinical Trials
- Fixed-Dose Trial in Early Parkinson's Disease (PD) Start of enrollment: 2019 Dec 13
Roles: Contact
- Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations (TEMPO-3) Start of enrollment: 2020 Sep 23
Roles: Contact
- Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease Start of enrollment: 2021 Nov 18
Roles: Contact, Principal Investigator
- Join now to see all
Publications & Presentations
PubMed
- 10 citationsUlotaront, a Trace Amine-Associated Receptor 1/Serotonin 5-HTAgonist, in Patients With Parkinson Disease Psychosis: A Pilot Study.Stuart H Isaacson, Mark Goldstein, Rajesh Pahwa, Carlos Singer, Kevin Klos
Neurology. Clinical Practice. 2023-08-01 - 34 citationsNerve safety of tanezumab, a nerve growth factor inhibitor for pain treatmentMark T. Brown, David N. Herrmann, Mark Goldstein, Aimee M. Burr, Michael D. Smith
Journal of the Neurological Sciences. 2014-10-15
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
